Business Wire

MA-PERKINELMER

20.4.2020 15:02:08 CEST | Business Wire | Press release

Share
PerkinElmer Launches Solutions to Streamline Analysis for Labs in Pharmaceuticals, Semiconductors, Biomonitoring, Food and Materials

PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today expanded its analysis and automation portfolio for quality, safety and content testing. Geared for pharmaceutical, semiconductor, biomonitoring, food, materials and academia labs, the new offerings will help streamline workflows, sharpen insights and performance and provide ease of use. They include:

NexION® 5000 Multi-Quadruple ICP-MS – for demanding trace element analyses, this solution drives accurate and repeatable results and helps future-proof labs. Leveraging new and proprietary technologies, it is the first in its category to offer four quadrupoles – meeting and exceeding rigorous trace-elemental testing requirements for labs working in areas like semiconductor R&D and device manufacturing as well as biomonitoring. The new offering goes beyond current triple-quad ICP-MS performance to deliver exceptionally low background equivalent concentrations (BECs) of <1 ppt even in hot plasma and outstanding detection limits in a matrix-tolerant, low-maintenance solution.

Spectrum™ 3 spectrometer – a tri-range FT-IR spectroscopy solution featuring 100 scans/second for pharmaceutical, polymer, materials, food, academic or chemical labs doing advanced research, product development or reaction monitoring. Working across solid, liquid or gas samples and including options for near, mid and far-IR ranges in one instrument, it brings strong flexibility. It is also suitable for users of varying skill levels as it is the first FT-IR platform to offer a fully integrated TG-IR hyphenation (EGA4000) solution.

For more advanced applications, the offering can be easily hyphenated with PerkinElmer’s TGA™ 8000 thermogravimetric analyzer and Clarus® SQ8 GC/MS chromatography system. Spectrum 3 also leverages PerkinElmer’s Spectrum™ 10 software (including integrated time resolved software and CFR 21 Part 11 compliance options) and cloud connectivity via NetPlus™ software – delivering accurate results, integrated workflows and global, real-time collaboration.

Spectrum™ Two + spectrometer - a powerful FT-IR solution for routine compositional and quality analyses that delivers fast and accurate results with secure, cloud-connectivity. It also offers a compact footprint, advanced UATR (universal attenuated total reflectance) accessory and rugged touchscreen.

S20 Autosamplers Series - brings sample automation speed, ruggedness and versatility to labs looking to boost their productivity and cost savings, as well as future-proof their spectroscopy capabilities.

“Whether lab professionals are working to ensure the efficacy of pharmaceuticals, meeting materials regulations, aiming for zero impurities in semiconductor processes, or testing for food adulteration, they want to be more productive and collaborative and create highly reliable results and fresh insights,” said Suneet Chadha, VP/GM, Applied Markets, PerkinElmer. “Our new four quadrupole ICP-MS, FT-IR and automation solutions are designed to empower scientists and technicians to look deeper, work smarter and prepare for future needs or requirements.”

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise at www.perkinelmer.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye